论文部分内容阅读
目的观察乳腺癌组织中PTPN12的表达情况,初步探讨其可能作用的蛋白,并分析其与临床病理参数及预后的关系。方法收集2005-2009年南方医院收治的84例乳腺癌患者的病理及临床资料,其中“三阴”乳腺癌患者50例,“非三阴”乳腺癌患者34例。采用免疫组化染色方法检测组织中PTPN12、EGFR的表达,并分析PTPN12表达与临床病理参数以及患者预后的关系。结果 “三阴”乳腺癌患者中PTPN12的缺失表达率、EGFR的阳性表达率显著高于“非三阴”乳腺癌患者(42.0%vs 20.6%,P=0.041;76.0%vs 47.1%,P=0.007)。PTPN12的表达与EGFR(rs=-0.208,P=0.058)、Her-2(rs=-0.250,P=0.022)存在负相关关系。PTPN12表达阴性的患者,其生存期更短。多因素分析表明PTPN12是乳腺癌独立的预后因子。结论PTPN12在“三阴”乳腺癌中具有更高的缺失突变,它的表达与EGFR和Her-2负相关。PTPN12是乳腺癌独立的预后因子。
Objective To observe the expression of PTPN12 in breast cancer and to explore its possible role in the protein and to analyze its relationship with clinicopathological parameters and prognosis. Methods The clinical data and clinical data of 84 cases of breast cancer from 2005 to 2009 in Southern Hospital were collected. Among them, there were 50 cases of Sanyin breast cancer and 34 cases of non-Sanyin breast cancer. The expression of PTPN12 and EGFR in tissues was detected by immunohistochemical staining. The relationship between the expression of PTPN12 and clinicopathological parameters and prognosis was analyzed. Results The positive expression rate of PTPN12 in patients with “triple negative” breast cancer was significantly higher than that in patients with “non-triple negative” breast cancer (42.0% vs 20.6%, P = 0.041; 76.0% vs 47.1 %, P = 0.007). The expression of PTPN12 was negatively correlated with EGFR (rs = -0.208, P = 0.058) and Her-2 (rs = -0.250, P = 0.022) Patients with negative PTPN12 expression have shorter survival. Multivariate analysis showed that PTPN12 was an independent prognostic factor for breast cancer. Conclusions PTPN12 has a higher deletion mutation in “Sanyin ” breast cancer, and its expression is negatively correlated with EGFR and Her-2. PTPN12 is an independent prognostic factor for breast cancer.